Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2011 - 2026)

Abeona Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 42.29% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at $69.9 million (up 207.59% YoY), while the FY2025 annual figure was $67.1 million, up 205.25% from the prior year.
• Net Income towards Common Stockholders was -$17.1 million for Q1 2026 at Abeona Therapeutics, up from -$21.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $113.7 million in Q2 2025 to a low of -$31.6 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged -$7.2 million across 5 years, with a median of -$12.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 247.25% in 2024, then soared 945.23% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$7.1 million in 2022, then plunged by 132.4% to -$16.6 million in 2023, then jumped by 44.02% to -$9.3 million in 2024, then slumped by 131.24% to -$21.5 million in 2025, then climbed by 20.54% to -$17.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$17.1 million (Q1 2026), -$21.5 million (Q4 2025), and -$5.2 million (Q3 2025), per Business Quant data.